-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongcheng Pharmaceutical (002675.SZ): 177 Lu-LNC1009 injection clinical trial approved. Currently, there are no products on the market at home or abroad

Zhitongcaijing·12/07/2025 10:01:03
Listen to the news

Zhitong Finance App News, Dongcheng Pharmaceutical (002675.SZ) announced that on December 5, 2025, the company's holding subsidiary Yantai Lannacheng Biotechnology Co., Ltd. (hereinafter referred to as “Lan Nacheng”) received a drug clinical trial approval notice for 177 Lu-LNC1009 injection approved and issued by the China National Drug Administration (hereinafter referred to as the “State Drug Administration”) and will conduct clinical trials in the near future.

The product being developed by the company, 177 Lu-LNC1009 injection is a dual-target radiotherapy drug targeting fibrocyte-activating protein (FAP) and integrin αvβ3. It is intended for the treatment of patients with advanced malignant solid tumors that are FAP positive and integrin αvβ3 positive. Currently, there are no similar products on the market at home or abroad, and there is no relevant sales data.